Education
About Us
Working with TipRanks
Follow Us
Nrx Pharmaceuticals, Inc. (NRXP)
:NRXP
NRXP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.10 - $6.01
Previous CloseN/A
Volume2.07M
Average Volume (3M)151.28K
Market Cap
$51.49M
Enterprise Value$36.49M
Total Cash (Recent Filing)$5.55M
Total Debt (Recent Filing)$8.40M
Price to Earnings (P/E)―
Beta1.03
Next Earnings
Aug 18, 2025EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding19,503,412
10 Day Avg. Volume125,340
30 Day Avg. Volume151,276
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.71
Enterprise Value/Revenue9.12K
Enterprise Value/Gross Profit36.49K
Enterprise Value/Ebitda-1.51
Forecast
1Y Price Target
$18.00Price Target Upside581.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Market PotentialThe current market for ketamine approaches $1B, and even a fraction of this market would be significant for NRXP.
Product DevelopmentNRXP is advancing a preservative-free ketamine via both ANDA and NDA pathways that could lead to a unique product in the market.
Strategic PartnershipsManagement has indicated significant interactions with developers of TMS equipment, suggesting strong strategic partnerships to offer comprehensive treatment solutions.
Bears Say
Developmental PhaseNRx Pharmaceuticals is a developmental-stage biotechnology company working in a large area of unmet need that has seen essentially no improvement in treatment outcomes in 50 years.
Financial StabilityCompany's cash and equivalents of $5.5M are expected to support operations through 2025, potentially limiting financial flexibility.
NRX Pharmaceuticals News
NRXP FAQ
What was Nrx Pharmaceuticals, Inc.’s price range in the past 12 months?
Nrx Pharmaceuticals, Inc. lowest stock price was $1.10 and its highest was $6.01 in the past 12 months.
What is Nrx Pharmaceuticals, Inc.’s market cap?
Nrx Pharmaceuticals, Inc.’s market cap is $51.49M.
When is Nrx Pharmaceuticals, Inc.’s upcoming earnings report date?
Nrx Pharmaceuticals, Inc.’s upcoming earnings report date is Aug 18, 2025 which is in 10 days.
How were Nrx Pharmaceuticals, Inc.’s earnings last quarter?
Nrx Pharmaceuticals, Inc. released its earnings results on May 15, 2025. The company reported -$0.34 earnings per share for the quarter, missing the consensus estimate of -$0.283 by -$0.057.
Is Nrx Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Nrx Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Nrx Pharmaceuticals, Inc. pay dividends?
Nrx Pharmaceuticals, Inc. does not currently pay dividends.
What is Nrx Pharmaceuticals, Inc.’s EPS estimate?
Nrx Pharmaceuticals, Inc.’s EPS estimate is -0.14.
How many shares outstanding does Nrx Pharmaceuticals, Inc. have?
Nrx Pharmaceuticals, Inc. has 19,503,412 shares outstanding.
What happened to Nrx Pharmaceuticals, Inc.’s price movement after its last earnings report?
Nrx Pharmaceuticals, Inc. reported an EPS of -$0.34 in its last earnings report, missing expectations of -$0.283. Following the earnings report the stock price went up 2.083%.
Which hedge fund is a major shareholder of Nrx Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in NRXP
NRX Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$18.00 (581.82% Upside)
$18.00 (581.82% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 8.1%
Last 30 Days ▼ 8.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.53%
12-Months-Change
Fundamentals
Return on Equity
108.28%
Trailing 12-Months
Asset Growth
100.37%
Trailing 12-Months
Company Description
Nrx Pharmaceuticals, Inc.
NRX Pharmaceuticals (NRXP) is a biopharmaceutical company focused on developing innovative therapies to address unmet needs in the treatment of central nervous system disorders and other critical health conditions. The company operates in the healthcare sector with a particular emphasis on drug development for serious mental illnesses, respiratory diseases, and other critical care indications. Its core products include investigational drugs designed to offer new treatment options for patients with severe mental health disorders and life-threatening pulmonary diseases.
NRXP Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in drug development, financial improvements, and strategic expansions in clinical networks. While there are regulatory and market risks, the advancements and potential market opportunities appear to outweigh the challenges.View all NRXP earnings summariesNRXP Stock 12 Month Forecast
Average Price Target
$18.00
▲(581.82% Upside)
Technical Analysis
Ownership Overview
7.78% Insiders
2.39% Mutual Funds
7.59% Other Institutional Investors
78.48% Public Companies and
Individual Investors